| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1033483228 |
| P356 | DOI | 10.1186/1741-7015-11-17 |
| P932 | PMC publication ID | 3606422 |
| P698 | PubMed publication ID | 23343013 |
| P5875 | ResearchGate publication ID | 235365747 |
| P50 | author | João E. Fonseca | Q43138417 |
| P2093 | author name string | Helena Canhão | |
| Vasco Crispim Romão | |||
| P2860 | cites work | Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates | Q45128012 |
| Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis | Q45163406 | ||
| Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment | Q45915302 | ||
| The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept | Q46114766 | ||
| Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis | Q46138285 | ||
| Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry | Q46212726 | ||
| Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug | Q46492181 | ||
| Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism | Q46496885 | ||
| Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year contin | Q46638118 | ||
| Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells | Q46721273 | ||
| Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients? | Q46754110 | ||
| Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis | Q46767407 | ||
| Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial | Q46778815 | ||
| 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis | Q46885439 | ||
| The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis. | Q46886554 | ||
| Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis | Q47317958 | ||
| Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients | Q47368536 | ||
| Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. | Q47774741 | ||
| Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients | Q47933816 | ||
| Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene | Q48386573 | ||
| Molecular action of methotrexate in inflammatory diseases | Q24534771 | ||
| MRP3, an organic anion transporter able to transport anti-cancer drugs | Q24650550 | ||
| Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study | Q24674942 | ||
| Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis | Q24812184 | ||
| Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis | Q24816803 | ||
| Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase | Q28207327 | ||
| Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis | Q28238667 | ||
| Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides | Q28263011 | ||
| Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis | Q28285444 | ||
| The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis | Q28306666 | ||
| Clinical liver disease in patients with rheumatoid arthritis taking methotrexate | Q28320836 | ||
| Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components | Q28343376 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient | Q32067920 | ||
| Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. | Q33362355 | ||
| Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis | Q33389401 | ||
| Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? | Q33565496 | ||
| The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. | Q33909650 | ||
| Low dose weekly methotrexate in early pregnancy. A case series and review of the literature | Q34012302 | ||
| 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q34130671 | ||
| Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis | Q34250833 | ||
| A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? | Q34385362 | ||
| Genetic studies, clinical heterogeneity, and disease outcome studies in rheumatoid arthritis | Q34526939 | ||
| The shared epitope and severity of rheumatoid arthritis | Q34526948 | ||
| Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis | Q34601833 | ||
| Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis | Q34634283 | ||
| Pharmacogenetics and folate metabolism -- a promising direction | Q34673321 | ||
| Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase | Q34686389 | ||
| Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review | Q34963241 | ||
| Evidence supporting the benefit of early intervention in rheumatoid arthritis | Q34999223 | ||
| Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. | Q35016515 | ||
| Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis | Q35082782 | ||
| In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register. | Q35082791 | ||
| Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort | Q57751478 | ||
| A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis | Q57788757 | ||
| A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions | Q57788773 | ||
| Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts | Q58234860 | ||
| Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis | Q58234919 | ||
| Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial | Q58234944 | ||
| Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis | Q59399994 | ||
| Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis | Q60699940 | ||
| Prognostic value of Th1/Th2 ratio in rheumatoid arthritis | Q61863540 | ||
| Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response | Q61912668 | ||
| Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis | Q61946755 | ||
| The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs | Q61946760 | ||
| Human thymidylate synthetase--III. Effects of methotrexate and folate analogs | Q66979074 | ||
| The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis | Q67567811 | ||
| The effect of age on methotrexate efficacy and toxicity | Q68014115 | ||
| Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: the effects of disease duration on treatment response | Q68163354 | ||
| Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro | Q68287945 | ||
| Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial | Q70750055 | ||
| Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis | Q71116275 | ||
| Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis | Q71595579 | ||
| Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study | Q71603077 | ||
| Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis | Q71634835 | ||
| Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo | Q71787842 | ||
| Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase | Q71806694 | ||
| The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group | Q72212788 | ||
| Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate | Q72296618 | ||
| Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology | Q72296676 | ||
| Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate | Q72610359 | ||
| The genetic basis of rheumatoid arthritis. The shared epitope hypothesis | Q35155219 | ||
| Cigarette smoking and rheumatoid arthritis severity | Q35547371 | ||
| Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study | Q35547691 | ||
| HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments | Q35547815 | ||
| Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy | Q35548151 | ||
| Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. | Q35551965 | ||
| Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage | Q35552357 | ||
| Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis | Q35552661 | ||
| Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene | Q35553306 | ||
| Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis | Q35553337 | ||
| Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study | Q35554180 | ||
| Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). | Q35554508 | ||
| Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). | Q35554533 | ||
| A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. | Q35554643 | ||
| Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression | Q35555003 | ||
| Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study | Q35555878 | ||
| Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis | Q35605590 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset | Q35637041 | ||
| Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis | Q35637808 | ||
| Sex: a major predictor of remission in early rheumatoid arthritis? | Q35638333 | ||
| Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation | Q35826792 | ||
| Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) | Q36204088 | ||
| Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis | Q36245665 | ||
| Genetic markers of treatment response in rheumatoid arthritis | Q36594231 | ||
| Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study | Q36641506 | ||
| Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside | Q36699052 | ||
| The pharmacogenetics of methotrexate | Q36857336 | ||
| Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate | Q36934649 | ||
| Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation | Q36948402 | ||
| Early rheumatoid arthritis -- is there a window of opportunity? | Q36994326 | ||
| Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? | Q37000103 | ||
| Role of interleukin-6 in the anemia of chronic disease | Q37108951 | ||
| An update on methotrexate pharmacogenetics in rheumatoid arthritis | Q37126658 | ||
| Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs | Q41921106 | ||
| Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study | Q41921976 | ||
| Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy | Q41922676 | ||
| Chloroquine therapy in patients with recent-onset rheumatoid arthritis: the clinical response can be predicted by the low level of acute-phase reaction at baseline | Q41922989 | ||
| Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group | Q41924053 | ||
| Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. | Q41928561 | ||
| Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications | Q41930813 | ||
| Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis | Q41931049 | ||
| Long-term second-line treatment: a prospective drug survival study | Q41940354 | ||
| Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. | Q41941295 | ||
| Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts | Q41943579 | ||
| Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. | Q41953736 | ||
| Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples | Q42203139 | ||
| A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity | Q42540064 | ||
| Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids | Q42603691 | ||
| The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis | Q42631739 | ||
| Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis | Q42723701 | ||
| Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. | Q42824941 | ||
| Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide | Q42853623 | ||
| Influence of HLA polymorphism on persistent remission in rheumatoid arthritis | Q43051230 | ||
| Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. | Q43073143 | ||
| Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis | Q43171700 | ||
| Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians | Q43245059 | ||
| Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis | Q43254415 | ||
| Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis | Q43261832 | ||
| Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study | Q43300360 | ||
| Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. | Q43413333 | ||
| Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors | Q43434557 | ||
| Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? | Q43498881 | ||
| A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression | Q43670878 | ||
| Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study | Q43683228 | ||
| The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients | Q43800679 | ||
| Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses | Q43943522 | ||
| Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis | Q44001428 | ||
| Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years | Q44087212 | ||
| Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia | Q44201573 | ||
| Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial | Q44205088 | ||
| The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses | Q44240544 | ||
| Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. | Q44255893 | ||
| Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients | Q44278878 | ||
| Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. | Q44396440 | ||
| Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis | Q44412980 | ||
| Remission in early rheumatoid arthritis: predicting treatment response | Q44415156 | ||
| Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis | Q44460291 | ||
| MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms | Q44539907 | ||
| Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. | Q44567896 | ||
| Prognostic markers of radiographic progression in early rheumatoid arthritis | Q44733614 | ||
| The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide | Q44791267 | ||
| Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis | Q44948330 | ||
| The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years | Q44972131 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells | Q45000646 | ||
| Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms | Q45070010 | ||
| Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis | Q72750229 | ||
| Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study | Q72767540 | ||
| Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial | Q72852710 | ||
| Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis | Q72922678 | ||
| Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis | Q73211158 | ||
| Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis | Q73373359 | ||
| Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration | Q73374696 | ||
| Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis | Q73573994 | ||
| The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis | Q73613525 | ||
| Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group | Q73632537 | ||
| Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment | Q73737600 | ||
| Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial | Q73891144 | ||
| Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy | Q74312812 | ||
| Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis | Q77174764 | ||
| The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria | Q77628776 | ||
| Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years | Q78109017 | ||
| Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate | Q78735344 | ||
| Polymorphism of HLA-DR and HLA-DQ in rheumatoid arthritis patients and clinical response to methotrexate--a hospital-based study | Q79402869 | ||
| ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients | Q79444592 | ||
| Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation | Q79528670 | ||
| Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients | Q79740389 | ||
| Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness | Q79996712 | ||
| Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease | Q80087673 | ||
| Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis | Q80201783 | ||
| Therapeutic strategies for rheumatoid arthritis | Q80209325 | ||
| Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice | Q80337026 | ||
| Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial | Q80419719 | ||
| Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis | Q80689354 | ||
| Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides | Q81045797 | ||
| Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study | Q81074699 | ||
| The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions | Q81178481 | ||
| Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis | Q81226278 | ||
| A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression | Q81235603 | ||
| Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients | Q81377140 | ||
| Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis | Q81380534 | ||
| The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis | Q82224041 | ||
| The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study | Q82645383 | ||
| Serum soluble CD30 in early arthritis: a sign of inflammation but not a predictor of outcome | Q82722235 | ||
| Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians | Q83018658 | ||
| Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery | Q83171989 | ||
| Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study | Q83239864 | ||
| Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis | Q83423023 | ||
| The challenges of methotrexate pharmacogenetics in rheumatoid arthritis | Q83545695 | ||
| Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial | Q83579024 | ||
| Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. | Q50612021 | ||
| Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. | Q50719785 | ||
| Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. | Q51155261 | ||
| Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. | Q51528833 | ||
| Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. | Q51751396 | ||
| Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. | Q51752635 | ||
| Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. | Q51776037 | ||
| Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. | Q51812393 | ||
| Patient-tailored therapy in rheumatoid arthritis: an editorial review. | Q52905385 | ||
| Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. | Q52919247 | ||
| A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. | Q53186873 | ||
| The MDR1 3435 polymorphism in patients with rheumatoid arthritis. | Q53882628 | ||
| Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. | Q53913241 | ||
| The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. | Q53988786 | ||
| Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. | Q54092884 | ||
| Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. | Q54358456 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| Markers of progression to rheumatoid arthritis: discriminative value of the new ACR/EULAR rheumatoid arthritis criteria in a Portuguese population with early polyarthritis | Q56966395 | ||
| [Practical guide for the use of biological agents in rheumatoid arthritis - December 2011 update] | Q56966420 | ||
| Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t | Q56966479 | ||
| Global Functional Status in Rheumatoid Arthritis: Disease Duration and Patient Age | Q56966607 | ||
| Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis | Q57169679 | ||
| Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatolog | Q57224416 | ||
| Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis | Q57348582 | ||
| Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis | Q84040588 | ||
| Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis | Q84760481 | ||
| Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate | Q37190006 | ||
| Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research | Q37342445 | ||
| Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? | Q37502462 | ||
| Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates | Q37524238 | ||
| Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis | Q37672592 | ||
| Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy | Q37740825 | ||
| Review of treatment response in rheumatoid arthritis: assessment of heterogeneity | Q37832733 | ||
| Rheumatoid arthritis: what is refractory disease and how to manage it? | Q37875394 | ||
| Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases | Q37946958 | ||
| Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. | Q38470451 | ||
| Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis | Q39617414 | ||
| Diagnostic value of antibodies to modified citrullinated vimentin in early rheumatoid arthritis | Q39652478 | ||
| Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis | Q39966214 | ||
| Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. | Q40338460 | ||
| A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels | Q40561489 | ||
| Predictors of infection in rheumatoid arthritis | Q40629895 | ||
| Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis | Q40886002 | ||
| Early rheumatoid arthritis: therapeutic strategies. | Q41054451 | ||
| The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis | Q41200879 | ||
| Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients | Q41723056 | ||
| How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial | Q41914450 | ||
| Ethnic differences in responses to disease modifying drugs | Q41915727 | ||
| Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. | Q41917077 | ||
| Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. | Q41917701 | ||
| Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset. | Q41917918 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| heterocyclic compound | Q193430 | ||
| methotrexate | Q422232 | ||
| disease-modifying antirheumatic drug | Q810254 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 17 | |
| P577 | publication date | 2013-01-23 | |
| P1433 | published in | BMC Medicine | Q4835947 |
| P1476 | title | Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? | |
| P478 | volume | 11 |
| Q48519138 | Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients? |
| Q35645491 | Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis |
| Q49527931 | Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models |
| Q53093606 | Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. |
| Q42219473 | Comparison of injectable doxorubicin & its nanodrug complex chemotherapy for the treatment of 4-nitroquinoline-1-oxide induced oral squamous cell carcinoma in rats |
| Q39154858 | DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis. |
| Q60304759 | Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis |
| Q90324412 | Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients |
| Q52665701 | Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. |
| Q47733654 | Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study |
| Q64927637 | How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. |
| Q48030951 | Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy |
| Q88957575 | Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate |
| Q35814091 | Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? |
| Q33747444 | Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms |
| Q55655944 | Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). |
| Q64123075 | Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate |
| Q33987886 | Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment |
| Q38182346 | Risk estimation in rheumatoid arthritis: from bench to bedside |
| Q52648362 | Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. |
| Q45055039 | SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients |
| Q28554987 | STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis |
| Q38267703 | Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? |
| Q36098311 | cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. |
Search more.